Detail akcie Vanda Pharma online

Business Summary: Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Vanda Pharmaceuticals Inc. revenues increased 3% to $51.7M. Net loss increased 65% to $48.6M. Revenues reflect Fanapt segment increase of 26% to $29.6M, PONVORY segment increase of 10% to $6.2M. Higher net loss reflects Selling, General and administrative - increase of 39% to $66.4M (expense), Other income decrease of 51% to $1.8M (income).